Low-Grade Ductal Carcinoma In Situ Improving Interobserver Reproducibility on the Path to Surveillance Strategies

被引:7
作者
Alghamdi, Sarah A. [1 ]
Krishnamurthy, Kritika [2 ]
Narvaez, Sofia A. Garces [2 ]
Algashaamy, Khaled J. [1 ]
Aoun, Jessica [1 ]
Reis, Isildinha M. [3 ]
Recine, Monica A. [2 ,5 ]
Jorda, Merce [3 ,4 ]
Poppiti, Robert J. [2 ,5 ]
Gomez-Fernandez, Carmen R. [3 ,4 ]
机构
[1] Univ Miami, Jackson Hlth Syst, Miami, FL 33146 USA
[2] Mt Sinai Med Ctr Florida, Miami Beach, FL USA
[3] Univ Miami, Dept Publ Hlth Sci, Miami, FL USA
[4] Univ Miami, Miller Sch Med, Miami, FL USA
[5] Florida Int Univ, Herbert Wertheim Coll Med, Miami, FL 33199 USA
关键词
Ductal carcinoma in situ; Interobserver reproducibility; Grading system; Low-grade DCIS; RANDOMIZED CLINICAL-TRIALS; BREAST-TUMOR RECURRENCES; LONG-TERM OUTCOMES; NSABP B-17; CANCER; LUMPECTOMY; MORTALITY; PROTOCOL; DCIS;
D O I
10.1093/ajcp/aqz179
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Objectives: We aimed to determine the interobserver reproducibility in diagnosing low-grade ductal carcinoma in situ (DCIS). We also aimed to compare the interobserver variability using a proposed two-tiered grading system as opposed to the current three-tiered system. Methods: Three expert breast pathologists and one junior pathologist identified low-grade DCIS from a set of 300 DCIS slides. Months later, participants were asked to grade the 300 cases using the standard three-tiered system. Results: Using the two-tiered system, interobserver agreement among breast pathologists was considered moderate (kappa = 0.575). The agreement was similar (kappa = 0.532) with the junior pathologist included. Using the three-tiered system, pathologists' agreement was poor (kappa = 0.235). Conclusions: Pathologists' reproducibility on diagnosing low-grade DCIS showed moderate agreement. Experience does not seem to influence reproducibility. Our proposed two-tiered system of low vs nonlow grade, where the intermediate grade is grouped in the nonlow category has shown improved concordance.
引用
收藏
页码:360 / 367
页数:8
相关论文
共 26 条
  • [1] Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor-Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24
    Allred, D. Craig
    Anderson, Stewart J.
    Paik, Soonmyung
    Wickerham, D. Lawrence
    Nagtegaal, Iris D.
    Swain, Sandra M.
    Mamounas, Elefetherios P.
    Julian, Thomas B.
    Geyer, Charles E., Jr.
    Costantino, Joseph P.
    Land, Stephanie R.
    Wolmark, Norman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (12) : 1268 - 1273
  • [2] Is DCIS Breast Cancer, and How Do I Treat it?
    Bijker, N.
    Donker, M.
    Wesseling, J.
    den Heeten, G. J.
    Rutgers, E. J. Th.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2013, 14 (01) : 75 - 87
  • [3] Digital mammography screening: Weighing reduced mortality against increased overdiagnosis
    de Gelder, Rianne
    Fracheboud, Jacques
    Heijnsdijk, Eveline A. M.
    den Heeten, Gerard
    Verbeek, Andre L. M.
    Broeders, Mireille J. M.
    Draisma, Gerrit
    de Koning, Harry J.
    [J]. PREVENTIVE MEDICINE, 2011, 53 (03) : 134 - 140
  • [4] Consistency in the observation of features used to classify duct carcinoma in situ (DCIS) of the breast
    Douglas-Jones, AG
    Morgan, JM
    Appleton, MAC
    Attanoos, RL
    Caslin, A
    Champ, CS
    Cotter, M
    Dallimore, NS
    Dawson, A
    Fortt, RW
    Griffiths, AP
    Hughes, M
    Kitching, PA
    O'Brien, C
    Rashid, AM
    Stock, D
    Verghese, A
    Williams, DW
    Williams, NW
    Williams, S
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2000, 53 (08) : 596 - 602
  • [5] Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study
    Elshof, Lotte E.
    Tryfonidis, Konstantinos
    Slaets, Leen
    van Leeuwen-Stok, A. Elise
    Skinner, Victoria P.
    Dif, Nicolas
    Pijnappel, Ruud M.
    Bijker, Nina
    Rutgers, Emiel J. Th.
    Wesseling, Jelle
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 (12) : 1497 - 1510
  • [6] The natural history of ductal carcinoma in situ of the breast:: a review
    Erbas, B
    Provenzan, E
    Armes, J
    Gertig, D
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 97 (02) : 135 - 144
  • [7] Re: Long-term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS
    Formenti, Silvia C.
    Arslan, Alan A.
    Pike, Malcolm C.
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (22) : 1723 - 1723
  • [8] Addressing overtreatment of screen detected DCIS; the LORIS trial
    Francis, Adele
    Thomas, Jeremy
    Fallowfield, Lesley
    Wallis, Matthew
    Bartlett, John M. S.
    Brookes, Cassandra
    Roberts, Tracy
    Pirrie, Sarah
    Gaunt, Claire
    Young, Jennie
    Billingham, Lucinda
    Dodwell, David
    Hanby, Andrew
    Pinder, Sarah E.
    Evans, Andrew
    Reed, Malcolm
    Jenkins, Valerie
    Matthews, Lucy
    Wilcox, Maggie
    Fairbrother, Patricia
    Bowden, Sarah
    Rea, Daniel
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 (16) : 2296 - 2303
  • [9] Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS)
    Groen, Emma J.
    Elshof, Lotte E.
    Visser, Lindy L.
    Rutgers, Emiel J. Th.
    Winter-Warnars, Hillegonda A. O.
    Lips, Esther H.
    Wesseling, Jelle
    [J]. BREAST, 2017, 31 : 274 - 283
  • [10] Clinical Trials for Ductal Carcinoma In Situ of the Breast
    Han, Michelle S.
    Khan, Seema A.
    [J]. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2018, 23 (04) : 293 - 301